Leukemia Research
Volume 29, Issue 8 , Pages 893-899 , August 2005

Over-expression of Flt3 induces NF-κB pathway and increases the expression of IL-6

  • Shinichiro Takahashi

      Affiliations

    • Department of Clinical Laboratory Medicine, Tohoku University School of Medicine, 1-1 Seiryou-machi, Aobaku, Sendai 980-8574, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 22 717 7373; fax: +81 22 717 7390.
    • ,
  • Hideo Harigae

      Affiliations

    • Department of Clinical Laboratory Medicine, Tohoku University School of Medicine, 1-1 Seiryou-machi, Aobaku, Sendai 980-8574, Japan
    • ,
  • Keiko Kumura Ishii

      Affiliations

    • Department of Clinical Laboratory Medicine, Tohoku University School of Medicine, 1-1 Seiryou-machi, Aobaku, Sendai 980-8574, Japan
    • ,
  • Mitsue Inomata

      Affiliations

    • Department of Rheumatology and Hematology, Tohoku University School of Medicine, 1-1 Seiryou-machi, Aobaku, Sendai 980-8574, Japan
    • ,
  • Tohru Fujiwara

      Affiliations

    • Department of Rheumatology and Hematology, Tohoku University School of Medicine, 1-1 Seiryou-machi, Aobaku, Sendai 980-8574, Japan
    • ,
  • Hisayuki Yokoyama

      Affiliations

    • Department of Rheumatology and Hematology, Tohoku University School of Medicine, 1-1 Seiryou-machi, Aobaku, Sendai 980-8574, Japan
    • ,
  • Kenichi Ishizawa

      Affiliations

    • Department of Rheumatology and Hematology, Tohoku University School of Medicine, 1-1 Seiryou-machi, Aobaku, Sendai 980-8574, Japan
    • ,
  • Junichi Kameoka

      Affiliations

    • Department of Rheumatology and Hematology, Tohoku University School of Medicine, 1-1 Seiryou-machi, Aobaku, Sendai 980-8574, Japan
    • ,
  • Jonathan D. Licht

      Affiliations

    • Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine, NY 10029, USA
    • ,
  • Takeshi Sasaki

      Affiliations

    • Department of Rheumatology and Hematology, Tohoku University School of Medicine, 1-1 Seiryou-machi, Aobaku, Sendai 980-8574, Japan
    • ,
  • Mitsuo Kaku

      Affiliations

    • Department of Clinical Laboratory Medicine, Tohoku University School of Medicine, 1-1 Seiryou-machi, Aobaku, Sendai 980-8574, Japan

Received 7 January 2005 ,Accepted 7 January 2005.

References 

  1. Thanos D, Maniatis T. NF-kappa B: a lesson in family values. Cell. 1995;80:529–532
  2. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, et al. Nuclear factor-kappa B is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301–2307
  3. Birkenkamp KU, Geugien M, Schepers H, Westra J, Lemmink HH, Vellenga E. Constitutive NF-kappa B DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia. 2004;18:103–112
  4. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532–1542
  5. Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia. 1997;11:1605–1609
  6. Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene. 2002;21:2555–2563
  7. Takahashi S, Mcconnell MJ, Harigae H, Kaku M, Sasaki T, Melnick AM, et al. The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT. Blood. 2004;103:4650–4658
  8. Takahashi S, Harigae H, Kaku M, Sasaki T, Licht JD. Flt3 mutation activates p21(WAF1/CIP1) gene expression through the action of STAT5. Biochem Biophys Res Commun. 2004;316:85–92
  9. Zheng R, Levis M, Piloto O, Brown P, Baldwin BR, Gorin NC, et al. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood. 2004;103:267–274
  10. Ozeki K, Kiyoi H, Hirose Y, Iwai M, Ninomiya M, Kodera Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood. 2004;103:1901–1908
  11. Takahashi S, Furuyama K, Kobayashi A, Taketani S, Harigae H, Yamamoto M, et al. Cloning of a coproporphyrinogen oxidase promoter regulatory element binding protein. Biochem Biophys Res Commun. 2000;273:596–602
  12. Tabellini G, Cappellini A, Tazzari PL, Fala F, Billi AM, Manzoli L, et al. Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. J Cell Physiol. 2005;202:623–634
  13. Malaguarnera L, Pilastro MR, Dimarco R, Scifo C, Renis M, Mazzarino MC, et al. Cell death in human acute myelogenous leukemic cells induced by pyrrolidinedithiocarbamate. Apoptosis. 2003;8:539–545
  14. Fujimaki S, Harigae H, Sugawara T, Takasawa N, Sasaki T, Kaku M. Decreased expression of transcription factor GATA-2 in haematopoietic stem cells in patients with aplastic anaemia. Br J Haematol. 2001;113:52–57
  15. Habelhah H, Frew IJ, Laine A, Janes PW, Relaix F, Sassoon D, et al. Stress-induced decrease in TRAF2 stability is mediated by Siah2. EMBO J. 2002;21:5756–5765
  16. Takahashi S, Harigae H, Yokoyama H, Kaku M, Sasaki T. Genomic structure and regulation of a novel human gene, Klp1. Biochim Biophys Acta. 2001;1522:207–211
  17. Romashkova JA, Makarov SS. NF-kappa B is a target of AKT in anti-apoptotic PDGF signalling. Nature. 1999;401:86–90
  18. Santos SC, Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood. 2004;103:3883–3889
  19. Wong GG, Witek-Giannotti JS, Temple PA, Kriz R, Ferenz C, Hewick RM, et al. Stimulation of murine hemopoietic colony formation by human IL-6. J Immunol. 1988;140:3040–3044
  20. Leary AG, Ikebuchi K, Hirai Y, Wong GG, Yang YC, Clark SC, et al. Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: comparison with interleukin-1 alpha. Blood. 1988;71:1759–1763
  21. Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19:624–631
  22. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326–4335
  23. Zhang S, Fukuda S, Lee Y, Hangoc G, Cooper S, Spolski R, et al. Essential role of signal transducer and activator of transcription (Stat)5a but not (Stat)5b for Flt3-dependent signaling. J Exp Med. 2000;192:719–728
  24. Nakamura T, Ouchida R, Kodama T, Kawashima T, Makino Y, Yoshikawa N, et al. Cytokine receptor common beta subunit-mediated STAT5 activation confers NF-kappa B activation in murine proB cell line Ba/F3 cells. J Biol Chem. 2002;277:6254–6265
  25. Kawashima T, Murata K, Akira S, Tonozuka Y, Minoshima Y, Feng S, et al. STAT5 induces macrophage differentiation of M1 leukemia cells through activation of IL-6 production mediated by NF-kappa B p65. J Immunol. 2001;167:3652–3660
  26. Griffin JD. Leukemia stem cells and constitutive activation of NF-kappa B. Blood. 2001;98:2291
  27. Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004;103:3669–3676

PII: S0145-2126(05)00052-4

doi: 10.1016/j.leukres.2005.01.008

Leukemia Research
Volume 29, Issue 8 , Pages 893-899 , August 2005

Article Tools

* Image Usage & Resolution